Keywords: Zeltia, Yondelis, PharmaMar, Financial results 2010
Spain’s Zeltia posts 74% rise in EBITDA, with Yondelis sales up 65% in 2010
Article | 28 February 2011
Spanish drugmaker Grupo Zeltia reported net revenues 153.5 million euros ($211.4 million) in 2010 up 24.4% on 2009, with most of the performance is primarily ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
